NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
61-75 of 394

Proactive Pregnancy Planning and Reproductive Care in MS
NeuroFrontiersProactive Pregnancy Planning and Reproductive Care in MS

Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
NeuroFrontiersApplying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis

Emerging Serum microRNAs as Early Signals in MS
NeuroFrontiersEmerging Serum microRNAs as Early Signals in MS

Advancing Pediatric MS Care: Insights from AAN 2026
NeuroFrontiersAdvancing Pediatric MS Care: Insights from AAN 2026
- advertisement

Family Planning in Patients with Multiple Sclerosis
NeuroFrontiersFamily Planning in Patients with Multiple Sclerosis

Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk

Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiersEarly ALS Patients Show Slowed Decline with Pridopidine Treatment

Rethinking Progression in Multiple Sclerosis
NeuroFrontiersRethinking Progression in Multiple Sclerosis

The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiersThe Burden of Cognitive Dysfunction in Multiple Sclerosis
- advertisement

Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiersWho’s Missing from Multiple Sclerosis Research?

GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiersGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen

CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiersCK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses


























